jumped more than 8% in after-hours action Monday after the business-software company widened its fiscal first-quarter profits. Excluding items, the Chelmsford, Mass., company earned $11.5 million, or 36 cents a share, in the quarter ended Dec. 30, compared with $11 million, or 34 cents a share, a year ago.
Analysts polled by Thomson Financial were looking for 33 cents. Revenue was up 16% to $148.7 million, which squeaks past the consensus. Shares were rising $2.79 to $36.79 in recent trading.
, which makes cardio-respiratory diagnostic systems, swung to a full-year profit and more than doubled its earnings for the fiscal fourth quarter. The St. Paul, Minn., small-cap said it made $1.4 million in the year ended Oct. 31, or 40 cents a share, compared with last year's loss of $919,000, or 25 cents a share.
Income for the quarter came to $755,000, or 21 cents a share, on revenue that surged 60.9% from a year ago to $10.7 million. Shares were gaining $1.37, or 8.6%, to $17.40.
(THLD - Get Report)
was higher after the Redwood City, Calif.-based company said it's starting patient enrollment for phase II testing on glufosfamide as a treatment for platinum-resistant ovarian cancer -- a condition that Threshold says constitutes almost half of all diagnosed ovarian cancer cases. Shares were up 19 cents, or 5.4%, to $3.70.
(CNET - Get Report)
rose on better-than-expected fourth-quarter results. The tech Web site operator's non-GAAP income fell 2 cents a share to $19.6 million, or 13 cents a share, but analysts had sought a penny less. Sales grew 14% to $118.4 million and beat the $111.8 million estimate.
For the quarter already in progress, the San Francisco-based company is expecting a bottom line between a loss of 2 cents and break-even a share on sales of between $90 million and $94 million. Analysts are looking for a 3-cent-per-share loss, on $91.8 million in revenue. Shares were adding 38 cents, or 4.5%, to $8.78.